MA38003A1 - Antibodies to the receptor antagonist prokinesin (prokrs) and their use - Google Patents

Antibodies to the receptor antagonist prokinesin (prokrs) and their use

Info

Publication number
MA38003A1
MA38003A1 MA38003A MA38003A MA38003A1 MA 38003 A1 MA38003 A1 MA 38003A1 MA 38003 A MA38003 A MA 38003A MA 38003 A MA38003 A MA 38003A MA 38003 A1 MA38003 A1 MA 38003A1
Authority
MA
Morocco
Prior art keywords
antibodies
prokrs
prokinesin
bind
receptor antagonist
Prior art date
Application number
MA38003A
Other languages
Arabic (ar)
French (fr)
Inventor
Lynn Macdonald
Michael L Lacroix-Fralish
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Priority claimed from PCT/US2013/069673 external-priority patent/WO2014078306A1/en
Publication of MA38003A1 publication Critical patent/MA38003A1/en

Links

Landscapes

  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne des anticorps qui se lient aux récepteurs de prokinéticine (prokr) et des procédés pour les utiliser. Selon certains modes de réalisation de l'invention, les anticorps sont des anticorps entièrement humains qui se lient à prokr1 et/ou prokr2 humains. La présente invention comprend des anticorps qui se lient à prokr1 et/ou prokr2 exprimés à la surface cellulaire. Dans certains modes de réalisation, les anticorps de la présente invention sont capables de bloquer l'activation médiée par la prokinéticine (pk) d'un ou plusieurs prokr. Les anticorps de l'invention sont utiles pour le traitement de diverses maladies et troubles médiés par la signalisation de la prokinéticine.The present invention relates to antibodies that bind to prokineticin receptors (prokr) and methods of using them. In some embodiments of the invention, the antibodies are fully human antibodies that bind to human prokr1 and / or prokr2. The present invention includes antibodies that bind to prokr1 and / or prokr2 expressed on the cell surface. In some embodiments, the antibodies of the present invention are capable of blocking prokineticin (pk) mediated activation of one or more prokr. The antibodies of the invention are useful for the treatment of various diseases and disorders mediated by prokineticin signaling.

MA38003A 2012-11-13 2013-11-12 Antibodies to the receptor antagonist prokinesin (prokrs) and their use MA38003A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261725704P 2012-11-13 2012-11-13
PCT/US2013/069673 WO2014078306A1 (en) 2012-11-13 2013-11-12 Anti-prokineticin receptor (prokr) antibodies and uses thereof

Publications (1)

Publication Number Publication Date
MA38003A1 true MA38003A1 (en) 2016-06-30

Family

ID=57197763

Family Applications (1)

Application Number Title Priority Date Filing Date
MA38003A MA38003A1 (en) 2012-11-13 2013-11-12 Antibodies to the receptor antagonist prokinesin (prokrs) and their use

Country Status (1)

Country Link
MA (1) MA38003A1 (en)

Similar Documents

Publication Publication Date Title
MA39313A1 (en) Anti-egfrviii antibodies and their uses in the treatment of various cancers
SG196835A1 (en) Human anti-b7rp1 neutralizing antibodies
MA32566B1 (en) ANTIBODIES THAT NEUTRALIZE HUMAN CYTOMEGALOVIRUSES AND USES THEREOF
MA39061A1 (en) Aplnr modulators and their uses
MA35620B1 (en) Compositions for the treatment of rheumatoid arthritis and methods of using the same
MA37945B1 (en) Human antibodies to gfr3 and methods of use thereof
MA33534B1 (en) Human antibodies have a high affinity against human 2 angiobots
MA42622B1 (en) LIAISONS IN TIGIT AND THEIR USES
PH12015500576A1 (en) Anti-notch3 agonist antibodies and their use in the treatment of notch3-related diseases
MA34749B1 (en) LOW AFFINITY HEMATO-ENCEPHALIC BARRIER ANTI-RECEPTOR ANTIBODIES AND USES THEREOF
ATE469658T1 (en) COMBINATION THERAPIES AGAINST MULTIPLE TOLL-LIKE RECEPTORS AND THEIR USE
MY165273A (en) Anti-cd48 antibodies and uses thereof
EA201070596A1 (en) HUMANIZED ANTIBODIES AGAINST TL1A
CL2008002886A1 (en) Constant region of a human antibody; anti-interleukin-6 (yl-6) receptor antibody and pharmaceutical composition comprising it.
MA31821B1 (en) Humanized anti-cxcr5 antibodies, their derivatives and their uses
MA38183A1 (en) Pyrrolopyrimidine compounds as kinase inhibitors
MA30128B1 (en) PHARMACEUTICAL COMBINATIONS OF ANGIOTENSIN RECEPTOR ANTAGONIST AND CIP INHIBITOR
MXPA06014510A (en) Compositions and methods for treating inflammatory disorders.
EA201100062A1 (en) CONNECTIONS AND METHODS OF MODELING RECEPTORS ASSOCIATED WITH PROTEIN G
TW200603828A (en) Treatment of disorders
TW200621244A (en) Modulators of muscarinic receptors
MA43767B1 (en) Non-antagonistic antibodies directed against the alpha chain of the extracellular domain of the il-7 receptor and their use in the treatment of cancer
WO2007059300A3 (en) Anti-alk antagonist and agonist antibodies and uses thereof
MX2007006382A (en) Modulators of muscarinic receptors.
MX2021015651A (en) Il1rap binding proteins.